Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemarituzumab in Combination Therapies for Advanced Gastric or Gastroesophageal Junction Cancer
NCT05322577Phase 2Terminated
- Sponsor
- Amgen
- Start
- May 2022
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, open-label trial of bemarituzumab in gastric cancer (GC) and gastroesophageal junction cancer (4 arms), sponsored by Amgen. Primary endpoints: Dose-limiting Toxicity, Treatment-emergent Adverse Event up to 30 months and 1 more. Started May 2022; status: terminated.
02
Drugs
bemarituzumab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT05322577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05322577.